Karl Georg Haeusler1, Christian Wollboldt2, Laura Zu Bentheim2, Juliane Herm2, Sebastian Jäger2, Claudia Kunze2, Holger-Carsten Eberle2, Claudia Christina Deluigi2, Oliver Bruder2, Carolin Malsch2, Peter U Heuschmann2, Matthias Endres2, Heinrich J Audebert2, Andreas J Morguet2, Christoph Jensen2, Jochen B Fiebach2. 1. From the Department of Neurology (K.G.H., C.W., L.z.B., J.H., M.E., H.J.A.) and Center for Stroke Research Berlin (K.G.H., C.K., M.E., H.J.A., J.B.F.), Charité - Universitätsmedizin Berlin, Germany; Contilia Heart and Vascular Center, Department of Cardiology and Angiology, Elisabeth-Krankenhaus, Essen, Germany (H.-C.E., C.C.D., O.B., C.J.); Department of Cardiology, Alexianer Berlin Krankenhaus Hedwigshöhe, Germany (S.J.); Institute of Clinical Epidemiology and Biometry, University Würzburg and Comprehensive Heart Failure Center, University of Würzburg, Clinical Trial Centre Würzburg, University Hospital Würzburg, Germany (C.M., P.U.H.); Department of Cardiology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Germany (A.J.M.); German Center for Neurodegenerative Diseases (DZNE), Partner Site Berlin, Germany (M.E.); and German Center for Cardiovascular Diseases (DZHK), Partner Site Berlin, Germany (M.E.); and Berlin Institute of Health, Germany (M.E.). georg.haeusler@charite.de. 2. From the Department of Neurology (K.G.H., C.W., L.z.B., J.H., M.E., H.J.A.) and Center for Stroke Research Berlin (K.G.H., C.K., M.E., H.J.A., J.B.F.), Charité - Universitätsmedizin Berlin, Germany; Contilia Heart and Vascular Center, Department of Cardiology and Angiology, Elisabeth-Krankenhaus, Essen, Germany (H.-C.E., C.C.D., O.B., C.J.); Department of Cardiology, Alexianer Berlin Krankenhaus Hedwigshöhe, Germany (S.J.); Institute of Clinical Epidemiology and Biometry, University Würzburg and Comprehensive Heart Failure Center, University of Würzburg, Clinical Trial Centre Würzburg, University Hospital Würzburg, Germany (C.M., P.U.H.); Department of Cardiology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Germany (A.J.M.); German Center for Neurodegenerative Diseases (DZNE), Partner Site Berlin, Germany (M.E.); and German Center for Cardiovascular Diseases (DZHK), Partner Site Berlin, Germany (M.E.); and Berlin Institute of Health, Germany (M.E.).
Abstract
BACKGROUND AND PURPOSE: Etiology of acute ischemic stroke remains undetermined (cryptogenic) in about 25% of patients after state-of-the-art diagnostic work-up. METHODS:One-hundred and three patients with magnetic resonance imaging (MRI)-proven acute ischemic stroke of undetermined origin were prospectively enrolled and underwent 3-T cardiac MRI and magnetic resonance angiography of the aortic arch in addition to state-of-the-art diagnostic work-up, including transesophageal echocardiography (TEE). We analyzed the feasibility, diagnostic accuracy, and added value of cardiovascular MRI (cvMRI) compared with TEE for detecting sources of stroke. RESULTS: Overall, 102 (99.0%) ischemic stroke patients (median 63 years [interquartile range, 53-72], 24% female, median NIHSS (National Institutes of Health Stroke Scale) score on admission 2 [interquartile range, 1-4]) underwent cvMRI and TEE in hospital; 89 (86.4%) patients completed the cvMRI examination. In 93 cryptogenic stroke patients, a high-risk embolic source was found in 9 (8.7%) patients by cvMRI and in 11 (11.8%) patients by echocardiography, respectively. cvMRI and echocardiography findings were consistent in 80 (86.0%) patients, resulting in a degree of agreement of κ=0.24. In 82 patients with cryptogenic stroke according to routine work-up, including TEE, cvMRI identified stroke etiology in additional 5 (6.1%) patients. Late gadolinium enhancement consistent with previous myocardial infarction was found in 13 (14.6%) out of 89 stroke patients completing cvMRI. Only 2 of these 13 patients had known coronary artery disease. CONCLUSIONS: Our study demonstrated that cvMRI was feasible in the vast majority of included patients with acute ischemic stroke. The diagnostic information of cvMRI seems to be complementary to TEE but is not replacing echocardiography after acute ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01917955.
RCT Entities:
BACKGROUND AND PURPOSE: Etiology of acute ischemic stroke remains undetermined (cryptogenic) in about 25% of patients after state-of-the-art diagnostic work-up. METHODS: One-hundred and three patients with magnetic resonance imaging (MRI)-proven acute ischemic stroke of undetermined origin were prospectively enrolled and underwent 3-T cardiac MRI and magnetic resonance angiography of the aortic arch in addition to state-of-the-art diagnostic work-up, including transesophageal echocardiography (TEE). We analyzed the feasibility, diagnostic accuracy, and added value of cardiovascular MRI (cvMRI) compared with TEE for detecting sources of stroke. RESULTS: Overall, 102 (99.0%) ischemic strokepatients (median 63 years [interquartile range, 53-72], 24% female, median NIHSS (National Institutes of Health Stroke Scale) score on admission 2 [interquartile range, 1-4]) underwent cvMRI and TEE in hospital; 89 (86.4%) patients completed the cvMRI examination. In 93 cryptogenic strokepatients, a high-risk embolic source was found in 9 (8.7%) patients by cvMRI and in 11 (11.8%) patients by echocardiography, respectively. cvMRI and echocardiography findings were consistent in 80 (86.0%) patients, resulting in a degree of agreement of κ=0.24. In 82 patients with cryptogenic stroke according to routine work-up, including TEE, cvMRI identified stroke etiology in additional 5 (6.1%) patients. Late gadolinium enhancement consistent with previous myocardial infarction was found in 13 (14.6%) out of 89 strokepatients completing cvMRI. Only 2 of these 13 patients had known coronary artery disease. CONCLUSIONS: Our study demonstrated that cvMRI was feasible in the vast majority of included patients with acute ischemic stroke. The diagnostic information of cvMRI seems to be complementary to TEE but is not replacing echocardiography after acute ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01917955.
Authors: Alexander E Merkler; Javid Alakbarli; Gino Gialdini; Babak B Navi; Santosh B Murthy; Parag Goyal; Jiwon Kim; Richard B Devereux; Monika M Safford; Costantino Iadecola; Hooman Kamel; Jonathan W Weinsaft Journal: J Stroke Cerebrovasc Dis Date: 2019-01-10 Impact factor: 2.136
Authors: M Kruska; C Fastner; J F Scheitz; A Kolb; M Rutsch; T Papavassiliu; M Borggrefe; A Alonso; I Akin; K Szabo; S Baumann Journal: Herz Date: 2020-07-06 Impact factor: 1.443
Authors: Karl Georg Haeusler; Christoph Jensen; Jan F Scheitz; Thomas Krause; Christian Wollboldt; Bernhard Witzenbichler; Heinrich J Audebert; Ulf Landmesser; Jochen B Fiebach; Christian H Nolte; Matthias Endres; Hans-Christian Mochmann Journal: Cerebrovasc Dis Extra Date: 2019-04-30
Authors: Simon Hellwig; Ulrike Grittner; Matthias Elgeti; Sebastian Wyschkon; Sebastian N Nagel; Jochen B Fiebach; Thomas Krause; Juliane Herm; Jan F Scheitz; Matthias Endres; Christian H Nolte; Karl Georg Haeusler; Thomas Elgeti Journal: ESC Heart Fail Date: 2020-07-15
Authors: Helena Stengl; Ramanan Ganeshan; Simon Hellwig; Edyta Blaszczyk; Jochen B Fiebach; Christian H Nolte; Axel Bauer; Jeanette Schulz-Menger; Matthias Endres; Jan F Scheitz Journal: JMIR Res Protoc Date: 2021-02-05
Authors: Renate B Schnabel; Stephan Camen; Fabian Knebel; Andreas Hagendorff; Udo Bavendiek; Michael Böhm; Wolfram Doehner; Matthias Endres; Klaus Gröschel; Andreas Goette; Hagen B Huttner; Christoph Jensen; Paulus Kirchhof; Grigorios Korosoglou; Ulrich Laufs; Jan Liman; Caroline Morbach; Darius Günther Nabavi; Tobias Neumann-Haefelin; Waltraud Pfeilschifter; Sven Poli; Timolaos Rizos; Andreas Rolf; Joachim Röther; Wolf Rüdiger Schäbitz; Thorsten Steiner; Götz Thomalla; Rolf Wachter; Karl Georg Haeusler Journal: Clin Res Cardiol Date: 2021-06-18 Impact factor: 5.460